<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04311632</url>
  </required_header>
  <id_info>
    <org_study_id>TCD601B102</org_study_id>
    <nct_id>NCT04311632</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Study in de Novo Renal Transplantation</brief_title>
  <official_title>A 12-Month, Randomized, Controlled, Open-Label, Dose Escalation Study Evaluating Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of an Anti-CD2 Monoclonal Antibody, TCD601(Siplizumab) Compared to Anti-thymocyte Globulin (rATG), as Induction Therapy in de Novo Renal Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ITB-Med LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ITB-Med LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and&#xD;
      pharmacodynamics of escalating doses of TCD601 when compared to rATG in de novo renal&#xD;
      transplant patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure Peak Plasma Concentration (Cmax) over time.</measure>
    <time_frame>12 months</time_frame>
    <description>The maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure the Area under the plasma concentration versus time curve (AUC).</measure>
    <time_frame>12 months</time_frame>
    <description>The AUC from time zero to the last measurable concentration sampling time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess changes in peripheral immunophenotype, including T-, B-, and NK-cells, via Fluorescence-activated Cell Sorter (FACS) over time.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure anti-TCD601 antibodies in serum via Enzyme-linked Immunosorbent (ELISA) assay over time.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure peripheral CD2-receptor occupancy following TCD601 administration</measure>
    <time_frame>12 months</time_frame>
    <description>Receptor Occupancy will be reported as the % of target saturation.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TCD601 administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TCD601 administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ATG administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TCD601</intervention_name>
    <description>Investigational Product</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus (TAC)</intervention_name>
    <description>Standard of Care Concomitant Immunosuppression</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroids (CS)</intervention_name>
    <description>Standard of Care Concomitant Immunosuppression</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil (MMF)</intervention_name>
    <description>Standard of Care Concomitant Immunosuppression</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG</intervention_name>
    <description>Standard of Care induction therapy in solid organ transplantation</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Able to understand the study requirements and provide written informed consent before&#xD;
             and study assessment is performed.&#xD;
&#xD;
          -  Male or female patients â‰¥ 18 to 70 years of age.&#xD;
&#xD;
          -  Recipients of a de novo renal allograft from a heart-beating deceased, living&#xD;
             unrelated, or non-HLA identical living related donor.&#xD;
&#xD;
          -  Recipients of a kidney with a cold ischemia time (CIT) less than 30 hours.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Multiple-organ transplant recipients&#xD;
&#xD;
          -  Subjects who have received a kidney allograft previously&#xD;
&#xD;
          -  Recipient of a kidney from an HLA identical living related donor&#xD;
&#xD;
          -  Recipient of a kidney from a donor after cardiac death&#xD;
&#xD;
          -  Subjects at high immunological risk for rejection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Slade, PharmD</last_name>
    <role>Study Chair</role>
    <affiliation>ITB-Med LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kellie Kennon, BSN</last_name>
    <phone>212-969-7823</phone>
    <email>ktx@itb-med.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel Baysa</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 12, 2020</study_first_submitted>
  <study_first_submitted_qc>March 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2020</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

